Genmab A/S (GMAB) Competitors

Genmab A/S (NASDAQ:GMAB) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, earnings, valuation, community ranking, institutional ownership, analyst recommendations, dividends and risk.

Is GMAB or TAK more profitable?

Genmab A/S has a net margin of 23.49% compared to Takeda Pharmaceutical's net margin of 6.49%. Genmab A/S's return on equity of 14.64% beat Takeda Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	23.49%	14.64%	12.37%
Takeda Pharmaceutical	6.49%	10.00%	4.78%

Does the media prefer GMAB or TAK?

In the previous week, Genmab A/S had 6 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 8 mentions for Genmab A/S and 2 mentions for Takeda Pharmaceutical. Genmab A/S's average media sentiment score of 0.98 beat Takeda Pharmaceutical's score of 0.58 indicating that Genmab A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genmab A/S	3 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Takeda Pharmaceutical	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has preferable earnings & valuation, GMAB or TAK?

Takeda Pharmaceutical has higher revenue and earnings than Genmab A/S. Genmab A/S is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$2.39B	5.77	$631.91M	$1.03	20.24
Takeda Pharmaceutical	$4.55T	0.01	$994.06M	$0.58	22.39

Does the MarketBeat Community prefer GMAB or TAK?

Genmab A/S received 61 more outperform votes than Takeda Pharmaceutical when rated by MarketBeat users. Likewise, 62.65% of users gave Genmab A/S an outperform vote while only 56.82% of users gave Takeda Pharmaceutical an outperform vote.

Company	Underperform	Outperform
Genmab A/S	Outperform Votes 161 62.65%	Underperform Votes 96 37.35%
Takeda Pharmaceutical	Outperform Votes 100 56.82%	Underperform Votes 76 43.18%

Do analysts prefer GMAB or TAK?

Genmab A/S presently has a consensus target price of $45.20, suggesting a potential upside of 116.80%. Given Genmab A/S's stronger consensus rating and higher possible upside, equities research analysts plainly believe Genmab A/S is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50
Takeda Pharmaceutical	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Which has more volatility & risk, GMAB or TAK?

Genmab A/S has a beta of 0.97, indicating that its stock price is 3% less volatile than the S&P 500. Comparatively, Takeda Pharmaceutical has a beta of 0.51, indicating that its stock price is 49% less volatile than the S&P 500.

Do institutionals & insiders believe in GMAB or TAK?

7.1% of Genmab A/S shares are held by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are held by institutional investors. 1.5% of Genmab A/S shares are held by insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Genmab A/S beats Takeda Pharmaceutical on 14 of the 18 factors compared between the two stocks.